Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Blessing C Ogboo

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Redox Biology|March 25, 2022
Architecture of the NADPH oxidase family of enzymesBlessing C Ogboo, Uriy V Grabovyy, Aniket Maini, et al.
Journal of Medicinal Chemistry|August 8, 2024
Demystifying Functional Parameters for Irreversible Enzyme InhibitorsDavid E Heppner, Blessing C Ogboo, Daniel A Urul, et al.
Journal of Medicinal Chemistry|December 22, 2023
Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor InhibitorsKristopher W Hoyt, Daniel A Urul, Blessing C Ogboo, et al.
Journal of Medicinal Chemistry|June 20, 2025
Enhancing Selectivity and Potency of S<sub>N</sub>Ar Covalent Inhibitors of NADPH Oxidase EnzymesBlessing C Ogboo, Kishan B Patel, Marta Massari, et al.
ACS Medicinal Chemistry Letters|December 15, 2022
Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)David E Heppner, Florian Wittlinger, Tyler S Beyett, et al.
Communications Chemistry|February 20, 2024
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitorsFlorian Wittlinger, Blessing C Ogboo, Ekaterina Shevchenko, et al.
Journal of Medicinal Chemistry|December 3, 2024
Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent "Type V" Kinase InhibitorsFlorian Wittlinger, Surbhi P Chitnis, Calvin D Pham, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Redox Biology|March 25, 2022
Architecture of the NADPH oxidase family of enzymesBlessing C Ogboo, Uriy V Grabovyy, Aniket Maini, et al.
Journal of Medicinal Chemistry|August 8, 2024
Demystifying Functional Parameters for Irreversible Enzyme InhibitorsDavid E Heppner, Blessing C Ogboo, Daniel A Urul, et al.
Journal of Medicinal Chemistry|December 22, 2023
Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor InhibitorsKristopher W Hoyt, Daniel A Urul, Blessing C Ogboo, et al.
Journal of Medicinal Chemistry|June 20, 2025
Enhancing Selectivity and Potency of S<sub>N</sub>Ar Covalent Inhibitors of NADPH Oxidase EnzymesBlessing C Ogboo, Kishan B Patel, Marta Massari, et al.
ACS Medicinal Chemistry Letters|December 15, 2022
Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)David E Heppner, Florian Wittlinger, Tyler S Beyett, et al.
Communications Chemistry|February 20, 2024
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitorsFlorian Wittlinger, Blessing C Ogboo, Ekaterina Shevchenko, et al.
Journal of Medicinal Chemistry|December 3, 2024
Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent "Type V" Kinase InhibitorsFlorian Wittlinger, Surbhi P Chitnis, Calvin D Pham, et al.
Pageof 1